Periprocedural major or life-threatening bleeding after TAVI occurs in 2.0-6.6% of patients and is associated with significant mortality rates of 14.1% at 30 days and 27.8% at one year.
This review highlights that while bleeding incidence after TAVI has declined, major bleeding still occurs in 2.0-6.6% of patients and carries high mortality, emphasizing the need for optimized antithrombotic therapy and access techniques.
Bleeding remains the most common complication following transcatheter aortic valve implantation (TAVI), despite a decline in its incidence over time. Periprocedural (≤30 days) major or life-threatening bleeding is reported to occur in 2.0-6.6% of patients undergoing TAVI. Major bleeding events carry a significant risk of mortality, with rates of 14.1% at 30 days and 27.8% at one year. The timely identification and management of patients at an elevated risk are therefore essential. Preventive measures include optimizing antithrombotic therapies, utilizing ultrasound-guided femoral access, employing single arterial access or a radial artery for secondary access, and administering unfractionated heparin under close monitoring. Long-term follow-up is essential for recognizing and managing late hemorrhages. In this review, we aimed to provide an in-depth analysis of bleeding events associated with TAVI and the most recent updates regarding the antithrombotic therapy of TAVI patients and its clinical impact.
Xenogiannis et al. (Fri,) conducted a review in Bleeding events after transcatheter aortic valve implantation (TAVI). Antithrombotic therapy and preventive measures was evaluated. Periprocedural major or life-threatening bleeding after TAVI occurs in 2.0-6.6% of patients and is associated with significant mortality rates of 14.1% at 30 days and 27.8% at one year.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: